New delivery systems for amphotericin B applied to the improvement of leishmaniasis treatment

Revista da Sociedade Brasileira de Medicina Tropical

Miguel Angel Chávez-fumagalli¹  Tatiana Gomes Ribeiro¹  Rachel Oliveira Castilho¹  Simone Odília Antunes Fernandes¹  Valbert Nascimento Cardoso¹  Cecília Steinberg Perilo Coelho¹  Débora Vasconcelos Costa Mendonça¹  Manuel Soto¹  Carlos Alberto Pereira Tavares¹  André Augusto Gomes Faraco¹  Eduardo Antonio Ferraz Coelho¹ 

关键词: Amphotericin B;    Leishmaniasis;    Nanoparticles;    Toxicity;    Treatment;    Lipid-based formulations;   

DOI  :  10.1590/0037-8682-0138-2015

来源: SciELO

【 摘 要 】

Leishmaniasis is one of the six major tropical diseases targeted by the World Health Organization. It is a life-threatening disease of medical, social and economic importance in endemic areas. No vaccine is yet available for human use, and chemotherapy presents several problems. Pentavalent antimonials have been the drugs of choice to treat the disease for more than six decades; however, they exhibit high toxicity and are not indicated for children, for pregnant or breastfeeding women or for chronically ill patients. Amphotericin B (AmpB) is a second-line drug, and although it has been increasingly used to treat visceral leishmaniasis (VL), its clinical use has been hampered due to its high toxicity. This review focuses on the development and in vivo usage of new delivery systems for AmpB that aim to decrease its toxicity without altering its therapeutic efficacy. These new formulations, when adjusted with regard to their production costs, may be considered new drug delivery systems that promise to improve the treatment of leishmaniasis, by reducing the side effects and the number of doses while permitting a satisfactory cost-benefit ratio.

【 授权许可】

CC BY   
 All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License